CBS 2019
CBSMD教育中心
中 文

双重抗血小板治疗持续时间

Abstract

Recommended Article

Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCI A Genotype-Guided Strategy for Oral P2Y12 Inhibitors in Primary PCI 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines Clopidogrel Pharmacogenetics: State-of-the-Art Review and the TAILOR-PCI Study Patient Selection and Clinical Outcomes in the STOPDAPT-2 Trial: An All-Comer Single-Center Registry During the Enrollment Period of the STOPDAPT-2 Randomized Controlled Trial 6-Month Versus 12-Month Dual-Antiplatelet Therapy Following Long Everolimus-Eluting Stent Implantation: The IVUS-XPL Randomized Clinical Trial Derivation, Validation, and Prognostic Utility of a Prediction Rule for Nonresponse to Clopidogrel: The ABCD-GENE Score Second-generation drug-eluting stent implantation followed by 6- versus 12-month dual antiplatelet therapy: the SECURITY randomized clinical trial
|<< 1 2 3 4 5 6 7 ...>>|

JOURNAL：CBS2017 Article Link

PADN Presented at ESC2017

CBS2017



Barcelona, Spain---European Society of Cardiology (ESC) , opened its annual congress to great fanfare at local time 8:30am on 28 August. Over 30,000 medical experts and practitioners are gathering together to Barcelona. The ESC is a world leading not-for-profit medical society in the discovery and dissemination of best practices in cardiovascular medicine. Until now, ESC unites 95,000 experts from 56 National Cardiac Societies, 46 cardiovascular ESC sub-specialty communities and 27 Affiliated Cardiac Societies around the world.




On the first day, ESC released guidelines in four clinical relevant domains: 2017 Focused update on Dual Antiplatelet Therapy (DAPT）; Management of Acute Myocardial Infarction in patients presenting with ST-segment elevation; Diagnosis and Treatment of Peripheral Arterial Diseases and Management of Valvular Heart Disease.




With low cure rate, high mortality rate and high therapy costs, pulmonary hypertension(PAH) is still a global public health issue. Some patients cannot benefit from standard medication therapy, even using multi target therapy. It is urgent to find another way than pharmacological treatment to solve more valuable lives. Prof Shaoliang Chen proposed innovatively pulmonary artery denervation in 2013 and presented their successful results from pre-clinical study to clincial study on the 27th at ESC2017.




From 9am to 10am on 28 August, the third day of ESC congress, Prof Chen will present another anticipated topic "coronary intervention" in ESC symposium 26!




This time, all ESC attendees could get further information at the conference site about CBS2017 which will begin on 30 November in Nanjing, China. As a frontier of left main and coronary bifurcation lesions, we sincerely welcome global cardiologists and experts come to Nanjing to share your new ideas and techniques for a better world.




>CBS CBS 2019

> CBS 2019 REGISTRATION

> CBS 2019 PROGRAM

> CBS 2019 CALL FOR SCIENCE

> CBS 2019 SPOTLIGHTS

 CBSMD

> CBSMD WEBSITE REGISTRATION

> EDUCATION CENTER

> RECOMMANDED PAPER

> TOP 10 RESEARCH PAPER

> PRE-READING

CBS 2019 CBS 2019 FACULTY Education Resource CBSMD Scientific Library
Copyright ⓒ CBS MD Nanjing China. All rights reserved. 京ICP备16025898号-11
联系我们| Top